Rhythm Pharmaceuticals Secures EU Approval for Imcivree to Treat Acquired Hypothalamic Obesity
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy RYTM?
Rhythm Pharmaceuticals announced the European Commission, or EC, has expanded the marketing authorization for Imcivree - setmelanotide - to include the treatment of obesity and control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity, or HO, due to hypothalamic injury or impairment. Acquired HO is a rare neuroendocrine disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or impairment. Rhythm estimates there are approximately 10,000 people living with acquired HO in Europe. The EC approval is based on results from the Phase 3 TRANSCEND trial of setmelanotide in acquired HO. The global study met its primary endpoint. Setmelanotide was generally well tolerated in the TRANSCEND study. With EU authorization in place, The company will now work to secure access on a country-by-country basis across Europe. Commercial launches are anticipated in 2027. The company's supplemental New Drug Application was approved by the FDA on March 19 for Imcivree to treat patients in the U.S. living with acquired HO.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 92.310
Low
123.00
Averages
140.62
High
167.00
Current: 92.310
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company's lead asset, IMCIVREE, is an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the Food and Drug Administration (FDA) to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged four years and older with acquired hypothalamic obesity, adult and pediatric patients two years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. In addition to it the Company is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rhythm Pharmaceuticals Surges 8% After Strong Quarterly Earnings Report
- Significant Revenue Growth: Rhythm Pharmaceuticals reported a nearly doubled revenue of $60.1 million in Q1, driven by its Imcivree drug, surpassing the analyst consensus estimate of $57 million, indicating strong market performance in the weight-loss sector.
- Improved Net Loss: The company's net loss widened to $56.7 million (or $0.83 per share), yet it was better than the expected loss of $0.86, suggesting some progress in cost management despite increased expenses.
- Accelerated Market Promotion: Following FDA approval for a new indication (hypothalamic obesity), Imcivree received over 150 patient start forms within six weeks, demonstrating robust market demand and rapid promotional capabilities.
- Strong European Market Performance: Rhythm's revenue in Europe surged by 27% quarter-over-quarter, primarily driven by strong demand in key markets like Germany and France, further boosting investor confidence in the company's growth prospects.
See More
RHYTHM PHARMACEUTICALS STOCK JUMPS 7.5% IN PREMARKET TRADING FOLLOWING Q1 REVENUE INCREASE
- Company Performance: Rhyme Pharmaceutical's shares increased by 7.5% in pre-market trading following the release of their Q1 revenue report.
- Revenue Growth: The company reported a rise in revenue for the first quarter, contributing to the positive market response.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: Rhythm Pharmaceuticals reported global net revenues of $60.1 million for Q1 2026, reflecting a 5% sequential increase from Q4 2025, indicating robust market performance, particularly with 61% of revenue generated in the U.S.
- IMCIVREE Launch Status: Since the FDA approval of IMCIVREE, the company has received over 150 start forms, with approximately 80% coming from new prescribers, demonstrating strong market reception and potential for future revenue growth.
- R&D and Expense Outlook: The company anticipates non-GAAP operating expenses for fiscal year 2026 to be between $385 million and $415 million, with R&D expenses projected at $197 million to $213 million, reflecting a commitment to ongoing product development.
- International Market Progress: Rhythm's NDA filing in Japan has been accepted, with approval and launch expected by the end of 2026, further expanding its international presence and enhancing the company's global competitiveness.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Report Analysis
- Earnings Performance: Rhythm Pharmaceuticals reported a Q1 2026 GAAP EPS of -$0.83, in line with expectations, while revenue reached $60.1 million, a 59.4% year-over-year increase, exceeding forecasts by $4.03 million, indicating strong growth momentum in the market.
- Cash Flow Status: As of March 31, 2026, the company had approximately $340.6 million in cash, cash equivalents, and short-term investments, down from $388.9 million as of December 31, 2025, reflecting challenges in cash management.
- FDA Approval Progress: Rhythm Pharmaceuticals discussed the FDA approval of IMCIVREE for acquired hypothalamic obesity, marking a significant advancement in drug development that could provide new revenue growth opportunities in the future.
- Clinical Trial Results: The company shared topline results and insights from the Phase 3 EMANATE trial, further solidifying its R&D capabilities in obesity treatment, which is expected to positively impact market confidence.
See More
Rhythm Pharmaceuticals to Announce Q1 Earnings on May 5
- Earnings Announcement: Rhythm Pharmaceuticals is set to release its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at -$0.86 and revenue forecast at $56.07 million, reflecting a significant 48.7% year-over-year growth potential.
- Historical Performance: Over the past year, Rhythm has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability and market confidence in the company's financial performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 2 upward revisions and 5 downward revisions, while revenue estimates have also experienced 2 upward and 5 downward revisions, highlighting analyst divergence and market uncertainty regarding the company's future performance.
- FDA Approval Impact: Recently, Rhythm Pharmaceuticals received FDA approval to expand the label for its lead drug IMCIVREE, a development that could enhance the company's competitive edge and drive future revenue growth.
See More
Rhythm Pharmaceuticals Expands IMCIVREE Approval in Europe
- Market Authorization Expansion: Rhythm Pharmaceuticals announced that the European Commission has approved the expansion of IMCIVREE for treating acquired hypothalamic obesity due to hypothalamic injury, marking a significant advancement in the company's rare disease portfolio.
- Clinical Trial Results: IMCIVREE achieved its primary endpoint in the Phase 3 TRANSCEND trial, demonstrating a 19.8% placebo-adjusted reduction in body mass index (BMI), validating its efficacy in treating hypothalamic obesity.
- Patient Population Size: It is estimated that over 10,000 individuals in both the U.S. and Europe are affected by acquired hypothalamic obesity, indicating a substantial market demand and growth opportunity for the drug.
- Future Commercial Plans: The company intends to seek country-by-country approval for IMCIVREE in Europe, with commercial launches expected by 2027, further driving growth in the biopharmaceutical market.
See More
Rhythm Pharmaceuticals Surges 8% After Strong Quarterly Earnings Report
- Significant Revenue Growth: Rhythm Pharmaceuticals reported a nearly doubled revenue of $60.1 million in Q1, driven by its Imcivree drug, surpassing the analyst consensus estimate of $57 million, indicating strong market performance in the weight-loss sector.
- Improved Net Loss: The company's net loss widened to $56.7 million (or $0.83 per share), yet it was better than the expected loss of $0.86, suggesting some progress in cost management despite increased expenses.
- Accelerated Market Promotion: Following FDA approval for a new indication (hypothalamic obesity), Imcivree received over 150 patient start forms within six weeks, demonstrating robust market demand and rapid promotional capabilities.
- Strong European Market Performance: Rhythm's revenue in Europe surged by 27% quarter-over-quarter, primarily driven by strong demand in key markets like Germany and France, further boosting investor confidence in the company's growth prospects.
See More
RHYTHM PHARMACEUTICALS STOCK JUMPS 7.5% IN PREMARKET TRADING FOLLOWING Q1 REVENUE INCREASE
- Company Performance: Rhyme Pharmaceutical's shares increased by 7.5% in pre-market trading following the release of their Q1 revenue report.
- Revenue Growth: The company reported a rise in revenue for the first quarter, contributing to the positive market response.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Call Highlights
- Revenue Growth: Rhythm Pharmaceuticals reported global net revenues of $60.1 million for Q1 2026, reflecting a 5% sequential increase from Q4 2025, indicating robust market performance, particularly with 61% of revenue generated in the U.S.
- IMCIVREE Launch Status: Since the FDA approval of IMCIVREE, the company has received over 150 start forms, with approximately 80% coming from new prescribers, demonstrating strong market reception and potential for future revenue growth.
- R&D and Expense Outlook: The company anticipates non-GAAP operating expenses for fiscal year 2026 to be between $385 million and $415 million, with R&D expenses projected at $197 million to $213 million, reflecting a commitment to ongoing product development.
- International Market Progress: Rhythm's NDA filing in Japan has been accepted, with approval and launch expected by the end of 2026, further expanding its international presence and enhancing the company's global competitiveness.
See More
Rhythm Pharmaceuticals Q1 2026 Earnings Report Analysis
- Earnings Performance: Rhythm Pharmaceuticals reported a Q1 2026 GAAP EPS of -$0.83, in line with expectations, while revenue reached $60.1 million, a 59.4% year-over-year increase, exceeding forecasts by $4.03 million, indicating strong growth momentum in the market.
- Cash Flow Status: As of March 31, 2026, the company had approximately $340.6 million in cash, cash equivalents, and short-term investments, down from $388.9 million as of December 31, 2025, reflecting challenges in cash management.
- FDA Approval Progress: Rhythm Pharmaceuticals discussed the FDA approval of IMCIVREE for acquired hypothalamic obesity, marking a significant advancement in drug development that could provide new revenue growth opportunities in the future.
- Clinical Trial Results: The company shared topline results and insights from the Phase 3 EMANATE trial, further solidifying its R&D capabilities in obesity treatment, which is expected to positively impact market confidence.
See More
Rhythm Pharmaceuticals to Announce Q1 Earnings on May 5
- Earnings Announcement: Rhythm Pharmaceuticals is set to release its Q1 2023 earnings on May 5 before market open, with consensus EPS estimate at -$0.86 and revenue forecast at $56.07 million, reflecting a significant 48.7% year-over-year growth potential.
- Historical Performance: Over the past year, Rhythm has beaten EPS estimates 75% of the time and revenue estimates 50% of the time, indicating a degree of stability and market confidence in the company's financial performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 2 upward revisions and 5 downward revisions, while revenue estimates have also experienced 2 upward and 5 downward revisions, highlighting analyst divergence and market uncertainty regarding the company's future performance.
- FDA Approval Impact: Recently, Rhythm Pharmaceuticals received FDA approval to expand the label for its lead drug IMCIVREE, a development that could enhance the company's competitive edge and drive future revenue growth.
See More
Rhythm Pharmaceuticals Expands IMCIVREE Approval in Europe
- Market Authorization Expansion: Rhythm Pharmaceuticals announced that the European Commission has approved the expansion of IMCIVREE for treating acquired hypothalamic obesity due to hypothalamic injury, marking a significant advancement in the company's rare disease portfolio.
- Clinical Trial Results: IMCIVREE achieved its primary endpoint in the Phase 3 TRANSCEND trial, demonstrating a 19.8% placebo-adjusted reduction in body mass index (BMI), validating its efficacy in treating hypothalamic obesity.
- Patient Population Size: It is estimated that over 10,000 individuals in both the U.S. and Europe are affected by acquired hypothalamic obesity, indicating a substantial market demand and growth opportunity for the drug.
- Future Commercial Plans: The company intends to seek country-by-country approval for IMCIVREE in Europe, with commercial launches expected by 2027, further driving growth in the biopharmaceutical market.
See More
